Serum arylesterase activity is negatively correlated with inflammatory markers in patients with acute coronary syndromes

Saudi Medical Journal

Volumn 30, Issue 3, 2009, Pages 334-339

  Senturk, Tunay ^a   Sarandol, Emre ^a   Gullulu, Sumeyye ^a   Erdinc, Selda ^a   Ozdabakoglu, Osman ^a   Ozdemir, Bulent ^a   Baran, Ibrahim ^a   Arslan, Sinan ^a   Aydinlar, Ali ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; HEPARIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NITRATE; PROCALCITONIN;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL FEATURE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ENZYME ACTIVITY; FEMALE; HEART INFARCTION; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; SPECTROPHOTOMETRY; ST SEGMENT ELEVATION; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALCITONIN; CARBOXYLIC ESTER HYDROLASES; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PROTEIN PRECURSORS; STATISTICS, NONPARAMETRIC;

EID: 67649235126     PISSN: 03795284     EISSN: 16583175     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Kaplan M, Aviram M. Oxidized low-density lipoprotein: Atherogenic and proinflammatory characteristics during macrophage foam cell formation. An inhibitory role for nutritional antioxidants and serum paraoxonase. Clin Chem Lab Med 1999; 37: 777-787.
2. Serdar Z, Aslan K, Dirican M, Sarandöl E, Yeşilbursa D, Serdar A. Lipid and protein oxidation and antioxidants status in patients with angiographically proven coronary artery disease. Clin Biochem 2006; 39: 794-803.
3. Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntryre TM, Prescot SM, et al. Anti-inflammatory HDL decomes pro-inflammatory during the acute phase response. Loos of protective effect of HDL against LDL oxidase in aortic wall cell cocultures. J Clin Invest 1995; 96: 2758-2767.
4. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991; 286: 152-154.
5. Aviram M, Rosenblat NT, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions: A possible peroxidative role for paraoxonase. J Clin Invest 1998: 101: 1581-1590.
6. Tward A, Xia YR, Wang XP, Shi YS, Park C, Castellani LW, et al. Decreased atheroscleotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002; 106: 484-490.
7. Oda MN, Bielicki JK, Ho TT, Berger T, Rubin EM, Forte TM. Paraoxonase 1 overexpression in mice and its effect om high-density lipoproteins. Biochem Biophys Res Commun 2002; 290: 921-927.
8. Inoue M, Suehiro T, Nakamura T, Ikeda Y, Kumon Y, Hashimoto K. Serum Arylesterase/Diazoxonase Activity and Genetic Polymorphisms in Patients With Type 2 Diabetes. Metabolism 2000; 49: 1400-1405.
9. Erren M, Reinecke H, Junker R, Fobker M, Schulte H, Schurek JO, et al. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol 1999; 19: 2355-2363.
10. Ilhan F, Akbulunt H, Karaca I, Godekmerdan A, Ilkay E, Bulut V. Procalcitonin, C-reactive protein and neopterin levels in patients with coronary atherosclesrosis. Acta Cardiol 2005; 60: 361-365.
11. Yeghiazarians Y, Braunstein JB, Askari A, Stone PH. Unstable Angina Pectoris. N Engl J Med 2000; 342: 101-104.
12. Fischer A, Gutstein DE, Fuster V. Thrombosis and coagulation abnormalities in the acute coronary syndromes. Cardiol Clin 1999; 17: 283-294.
13. Forrester JS. Role of plaque rupture in acute coronary syndromes. Am J Cardiol 2000; 86: J15-J23.
14. Plutzky J. Inflammatory pathways in atherosclerosis and acute coronary syndromes. Am J Cardiol 2001; 88: K10-K5.
15. Brunetti ND, Troccoli R, Correale M, Pellegrino PL, Biase MD. C-reactive protein in patients with acute coronary syndrome: Correlation with diagnosis, myocardial damage, ejection fraction and angiographic findings. International Journal of Cardiology 2006; 109: 248-256.
16. Zairis MN, Manousakis SJ, Stefanidis AS, Papadaki OA, Adrikopoulos GK, Olympios CD, et al. C-reactive protein levels on admission are associated with response to thrombolysis and pronosis after ST-segment elevation acute myocardial infarction. Am Heart J 2002; 144: 782-789.
17. Gheno G, Libardoni M, Zeppellini R, Cucchini F. C-reactive protein on admission as a predictor of in-hospital death in the elderly with acute myocardial infarction. Cardiologia 1999; 44: 1023-1028.
18. de Winter RJ, Bholasingh R, Lijmer JG, Koster RW, Gorgels JP, Shouten Y, et al. Independent prognostic value of C-reactive protein and troponin I in patients with unstable angina or non-Q-wave myocardial infarction. Cadiovasc Res 1999; 42: 240-245.
19. Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN. Serum paraoxonate after myocardial infarction. Arterioscler Thromb Vasc Biol 1999; 19: 330-335.
20. Kabaroglu C, Mutaf I, Boydak B, Ozmen D, Habif S, Erdener D, et al. Association between serum paraoxonate activity and oxidative stress in acute coronary syndromes. Acta Cardiol 2004; 59: 606-611.
21. Feingold KR, Memon RA, Moser AH, Grunfeld C. Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 1998; 139: 307-315.
22. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiolgy Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36: 959-969.
23. Braunwald E. Unstable angina. A classification. Circulation 1989; 80: 410-414.
24. Eckerson HW, Wyte MC, La Du BN. The Human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983; 35: 1126-1138.
25. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
26. Kleemola P, Freese R, Jauhiainen M, Pahlman R, Alfthan G, Mutanen M. Dietary determinants of serum paraoxonase activity in healthy humans. Atherosclerosis 2002; 160: 425-432.
27. James RW, Leviev I, Righetti A. Smoking is associated with reduced serum paraoxonase activity and concentration in patients wih coronary artery disease. Circulation 2000; 101: 2252-227.
28. Jarvik GP, Tsai NT, McKinstry LA, Wani R, Brophy VH, Richter RJ, et al. Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscler Thomb Vasc Biol 2002; 22: 1329-1333.
29. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA. Paraoxonase: Biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996; 7: 69-76.
30. Mackness MI, Harty D, Bharnagar D, Winocour PH, Arrol S, Ishola M, et al. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991; 86: 193-198.